How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area

Table 2

Eligibility criteria for the EMPA-REG OUTCOME (empagliflozin) trial and number of patients in the SIDIAP database that would have met criteria for enrolment.

Eligibility criteria in EMPA-REG OUTCOME trial	Potentially eligible patients from the SIDIAP database ()
Inclusion criteria	(%)
years	373,185 (100)
Preexisting CV event: CHD, angina, MI, stroke, and PAD	86,534 (23.2)
HbA1c level 7.0%-≤10.0%	33,270 (8.9)
Main exclusion criteria	(%)
	2,488 (0.7)
	223 (0.06)
Total eligible, (%)	30,559 (8.2)

CHD: coronary heart disease; CV: cardiovascular; eGFR: estimated glomerular filtration rate; MI: myocardial infarction; PAD: peripheral artery disease; HbA1c: glycated haemoglobin; BMI: body mass index. All the percentages refer to the proportion from the total number of eligible subjects of the SIDIAP database ().